Overall Survival and Response with Nivolumab and Relatlimab in Advanced Melanoma

Autor: Georgina V. Long, F. Stephen Hodi, Evan J. Lipson, Dirk Schadendorf, Paolo A. Ascierto, Luis Matamala, Pamela Salman, Erika Castillo Gutiérrez, Piotr Rutkowski, Helen J. Gogas, Christopher D. Lao, Juliana Janoski De Menezes, Stéphane Dalle, Ana Arance, Jean-Jacques Grob, Sarah Keidel, Anadil Shaikh, Anne Marie Sobiesk, Sonia Dolfi, Hussein A. Tawbi

Publikováno v: NEJM Evidence. 2

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::e648ee5c9667edd89181164cc2f6e4c6
https://doi.org/10.1056/evidoa2200239

First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in advanced non-small-cell lung cancer: CheckMate 9LA 2-year update

Autor: X. Zhang, Michael Schenker, Shunyuan Lu, Arnaud Scherpereel, Maurice Pérol, A. Lingua, Manuel Cobo, S. Marimuthu, Tudor-Eliade Ciuleanu, Arteid Memaj, Eduardo Richardet, O. Juan-Vidal, F. Reyes, David P. Carbone, B. Zurawski, A. Alexandru, Phuong Tran, Hiroshi Sakai, Jaafar Bennouna, Martin Reck, Enriqueta Felip, Thomas John, Juliana Janoski de Menezes, Pierre-Jean Souquet, C. Martin, Luis Paz-Ares, P. De Marchi

Publikováno v: ESMO Open
ESMO Open, 2021, 6 (5), pp.100273. ⟨10.1016/j.esmoop.2021.100273⟩
Scientia
Esmo Open
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname

Background To further characterize survival benefit with first-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone, we report updated data from the phase III CheckMate 9LA trial with a 2-year minimum follow-up. Pa

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c9589559f779d6c7e2f62cb2eac8678f
https://www.hal.inserm.fr/inserm-03540859/document

First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial

Autor: Pierre-Jean Souquet, David P. Carbone, Michael Schenker, Shun Lu, S. Meadows-Shropshire, A. Alexandru, Pamela Salman, Hiroshi Sakai, Jaafar Bennouna, Maurice Pérol, Enriqueta Felip, Alejo Lingua, J. Yan, Juliana Janoski de Menezes, B. Zurawski, Martin Reck, Arnaud Scherpereel, C. Martin, Eduardo Richardet, Abderrahim Oukessou, Tudor-Eliade Ciuleanu, Manuel Cobo, O. Juan-Vidal, Pedro Rafael Martins De Marchi, Thomas John, Luis Paz-Ares, Shruti Agrawal

Publikováno v: LANCET ONCOLOGY
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname
Lancet
Lancet, Elsevier, 2021, 22 (2), pp.198-211. ⟨10.1016/S1470-2045(20)30641-0⟩
The Lancet
The Lancet, 2021, 22 (2), pp.198-211. ⟨10.1016/S1470-2045(20)30641-0⟩

Erratum in Correction to Lancet Oncol 2021; 22: 198-211. [No authors listed] Lancet Oncol. 2021 Mar;22(3):e92. doi: 10.1016/S1470-2045(21)00082-6. PMID: 33662299 No abstract available.; International audience; Background: First-line nivolumab plus ip

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aa94d86fd54759cc80a6aa8c6a4c99f6
https://fundanet.iislafe.san.gva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=13780

First-line (1L) nivolumab (NIVO) + ipilimumab (IPI) + 2 cycles of chemotherapy (chemo) versus chemo alone (4 cycles) in patients (pts) with metastatic non–small cell lung cancer (NSCLC): 3-year update from CheckMate 9LA

Autor: Luis G. Paz-Ares, Tudor-Eliade Ciuleanu, Manuel Cobo-Dols, Jaafar Bennouna, Ying Cheng, Hideaki Mizutani, Alejo Lingua, Felipe Reyes, Niels Reinmuth, Juliana Janoski De Menezes, Jacek Jassem, Svetlana Protsenko, Kynan Feeney, Emmanuel De La Mora Jimenez, Shun Lu, Tom John, David Paul Carbone, Xiaoqing Zhang, Nan Hu, Martin Reck

Publikováno v: Journal of Clinical Oncology. 40:LBA9026-LBA9026

LBA9026 Background: In CheckMate 9LA (NCT03215706), 1L NIVO + IPI combined with 2 cycles of chemo was shown to provide survival benefit vs chemo alone in pts with metastatic NSCLC. Here, we report updated efficacy and safety with a 3-year minimum fol

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::0740151d5d852cc50a6bea934cb00193
https://doi.org/10.1200/jco.2022.40.17_suppl.lba9026

Olaparib plus abiraterone as first-line therapy in men with metastatic castration-resistant prostate cancer: Pharmacokinetics data from the PROpel trial

Autor: Andrew J. Armstrong, Noel W. Clarke, Antoine Thiery-Vuillemin, Mototsugu Oya, Giuseppe Procopio, Juliana Janoski De Menezes, Gustavo Colagiovanni Girotto, Pooja Ghatalia, Franco Nole, Omar Din, Philipp Spiegelhalder, Ivan Mincik, Robbert J. van Alphen, Nicolaas Lumen, Christian Hosius, Diansong Zhou, Laura Barker, Melanie Elizabeth Dujka, Fred Saad

Publikováno v: Journal of Clinical Oncology. 40:5050-5050

5050 Background: PROpel (NCT03732820) is a double-blind, Phase III trial of abiraterone + olaparib vs abiraterone + placebo as first-line treatment in patients with metastatic castration-resistant prostate cancer (mCRPC). Here we report results from

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::0d2d17b9190c7ec61b4745c51e549183
https://doi.org/10.1200/jco.2022.40.16_suppl.5050